Callejas González F J, Genovés Crespo M, Cruz Ruiz J, Godoy Mayoral R, Agustín Martínez F J, Martínez García A J, Tárraga López P J
a Department of Respiratory Medicine , Albacete University Hospital , Albacete , Spain.
b Department of Thoracic Surgery , Albacete University Hospital , Albacete , Spain.
Expert Rev Respir Med. 2016 Sep;10(9):1023-33. doi: 10.1080/17476348.2016.1188693. Epub 2016 May 23.
Chronic obstructive pulmonary disease (COPD) is a respiratory problem with the highest prevalence and strongest socio-economic impact in the world and whose morbimortality keeps increasing. Treating this disease is a challenge in the field of pneumology since the market now offers a wide range of bronchodilators. Tiotropium bromide, a long-acting anticholinergic bronchodilator, is a drug used to deal with this pathology.
The UPLIFT study was a 4-year (2004-2008) clinical multi-center trial in which tiotropium bromide was compared with a placebo. We present a bibliographic resume covering the multiple sub-analyses published since the end of the clinical trial, between 2009-2015. These sub-analyses analyzed the results obtained in UPLIFT in parallel, provided additional data about safety profiles, exacerbations, hospitalization and mortality rates, and lung function, among others. Expert Commentary: Tiotropium bromide is a significant advance for the maintenance treatment of patients with COPD. The favorable results obtained leave the door open to the possibility of improving the natural history of COPD and confirmed tiotropium bromide as the gold standard drug as monotherapy for treatment of COPD.
慢性阻塞性肺疾病（COPD）是一种在全球范围内患病率最高且社会经济影响最大的呼吸系统疾病，其发病率和死亡率持续上升。由于市场上现有多种支气管扩张剂，因此治疗这种疾病对肺病学领域而言是一项挑战。噻托溴铵是一种长效抗胆碱能支气管扩张剂，是用于治疗这种病症的药物。
UPLIFT研究是一项为期4年（2004 - 2008年）的临床多中心试验，其中将噻托溴铵与安慰剂进行了比较。我们展示了一份文献综述，涵盖了自2009年至2015年临床试验结束后发表的多项亚组分析。这些亚组分析并行分析了UPLIFT研究中获得的结果，提供了有关安全性、急性加重、住院率和死亡率以及肺功能等方面的额外数据。
噻托溴铵是COPD患者维持治疗方面的一项重大进展。所获得的良好结果为改善COPD自然病程的可能性敞开了大门，并确认噻托溴铵作为COPD单一疗法的金标准药物。
